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Dexmedetomidine is a potent and selective a2-adrenoceptor agonist used for perioperative and intensive care sedation. Compared with other drugs currently used for intensive care sedation, it has certain beneficial qualities such as lack of respiratory depression, 1 improved haemodynamic stability, 2 reduced stress responses to noxious stimuli, 3 alleviation of pain, 3 reduced incidence of delirium compared with benzodiazepines, 4 5 and possibly shorter length of stay in the intensive care unit (ICU). 6 There are reports suggesting that dexmedetomidine inhibits gastric emptying and gastrointestinal transit in rats, 7 8 an unwanted effect if it occurs in intensive care patients. Only one study has assessed the gastrointestinal effects of dexmedetomidine infusion in humans, and the low dose of dexmedetomidine used did not significantly inhibit gastric emptying. 9 Other previous studies on the gastrointestinal effects of a2-adrenoceptor agonists have yielded contradictory results. Clonidine did not inhibit gastric emptying in humans, 10 11 but dexmedetomidine and clonidine inhibited gastric emptying in rats to some extent, 7 8 whereas dexmedetomidine had no effect on gastric emptying in mice. 12 The results on gastrointestinal transit seem to be more consistent: both clonidine and dexmedetomidine inhibited gastrointestinal transit in most studies, both in humans and in rodents. 7 8 12-14 As the gastrointestinal effects of high-dose infusions of dexmedetomidine in humans were unknown, we designed this study using clinically relevant doses of dexmedetomidine to assess its effects on gastric emptying and oro-caecal transit in healthy volunteers. We chose a dosage of dexmedetomidine equal to the maximum suggested dose for sedation of ICU patients. A three-way cross-over study design was used to compare dexmedetomidine infusions with placebo (presumably no effect) and morphine (presumably a significant effect). Absorption of paracetamol was used as a measure of gastric emptying, and the hydrogen breath test was used to determine oro-caecal transit time.
Methods

Study subjects
The study (EudraCT number 2009-018170-66/ClinicalTrials.gov identifier NCT01084473) was conducted according to the revised Declaration of Helsinki of the World Medical Association and ICH guidelines for good clinical trial practice. The study protocol was approved by the Ethics Committee of the Hospital District of Southwest Finland and the Finnish Medicines Agency. The study underwent limited monitoring by a qualified representative of Turku Clinical Research Centre.
Healthy, unmedicated males older than 18 yr and weighing more than 60 kg were eligible for the study. Subject candidates with drug allergy, alcohol or drug abuse, significant psychological problems, positive urine drug screen, a 'yes' answer to any of the questions of a modified Finnish version of the Abuse Questionnaire, 15 a special diet or lifestyle, a BMI .30 kg m 22 or clinically significant abnormal findings in physical examination, ECG, or routine laboratory screening were not considered eligible for the study.
Smoking was prohibited during and within 4 weeks before the study. Subjects had to avoid drugs known to cause enzyme induction or inhibition for 30 days, any medications and some natural products (including grapefruit products) for at least 14 days, and alcohol and caffeine-containing products for at least 24 h. Ibuprofen was allowed for occasional headache or other conditions.
On the day before each study session, subjects were not allowed to eat foods rich in fibre or long-chain carbohydrates (such as rye bread, porridge, other full grain products, pasta, vegetables, fruits, berries). Eating and physical exercise were not allowed for 12 h, water intake for 4 h, and sleeping for 1 h before session start. On study days, subjects had to fast until an increase in exhaled hydrogen was detected or at least 4 h after lactulose administration.
A venous catheter was inserted into a large forearm vein for study drug administration and another into an antecubital vein in the opposite extremity for blood sampling. ECG, non-invasive arterial pressure, and arteriolar oxygen saturation (Sp O 2 ) were monitored for safety purposes.
Study treatments
A three-period cross-over design with balanced randomization was used. The wash-out period between consecutive administrations was at least 7 days. Subjects were given three different treatments in a randomized order: After running the infusions for 30 min, the subjects were given paracetamol 1 g per os (Panadol Forte w , GlaxoSmithKline Consumer Healthcare A/S, Copenhagen, Denmark) with 100 ml of tap water (258C), and 10 g of lactulose (Laktulos Merck NM w 667 mg ml 21 , Merck NM AB, Stockholm, Sweden) with 50 ml of tap water.
Assessment of gastric emptying
Venous blood samples were collected immediately before administration of paracetamol (baseline) and thereafter at 10, 20, 30, 40, 50, 60, 70, 80 min and 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, and 4 h. Plasma paracetamol concentrations were measured using reversed-phase high-performance liquid chromatography. 16 The lower limit of plasma paracetamol quantification was 0.1 mg litre 21 . Gastric emptying was assessed by the rate of paracetamol absorption using the time to peak plasma concentration, the peak plasma concentration, and the area under the plasma concentrationtime curve.
Assessment of oro-caecal transit time
Hydrogen is produced and exhaled when lactulose, an unabsorbable disaccharide, is fermented by colonic bacteria. The time between ingestion of lactulose and an increase in exhaled hydrogen represents the oro-caecal transit time. 17 18 The hydrogen concentration in exhaled air was measured with a hand-held device (Gastro + Gastrolyzer w , Bedfont Scientific Ltd, Rochester, Kent, UK) immediately before administration of lactulose (baseline) and thereafter at 15 min intervals, and the time between lactulose intake and the first occurrence of a sustained increase in exhaled hydrogen concentration (i.e. an increase of .10 ppm above baseline in at least three consecutive measurements) was taken as a measure of the oro-caecal transit time.
Pharmacokinetic analysis of paracetamol
The peak plasma paracetamol concentrations (C max ) and the corresponding time points (T max ) were measured. Areas under the paracetamol plasma concentration-time curves from 0 to 90 min were estimated using the trapezoidal rule (AUC 0 -90 min ). We used the linear trapezoidal rule when successive concentration values were increasing and the logarithmic trapezoidal rule when successive concentration values were decreasing after the observed peak concentration. Data were analysed using the WinNonlin pharmacokinetic program (version 4.1; Pharsight, Mountain View, CA, USA).
Statistical analysis
On the basis of previous studies, 9 we calculated that 10 subjects would be required to demonstrate a 30% difference in The protocol-specified outcome variables were time to peak paracetamol concentration, peak paracetamol concentration, area under the plasma concentration -time curve of paracetamol, and oro-caecal transit time.
Results
Study subjects
The median age of the 12 subjects was 21 (20-26) yr, median weight was 77 (61 -85) kg, and height was 1.84 (1.69 -1.93) m.
Gastric emptying
Median concentrations of paracetamol in plasma during the three phases of the study are shown in Figure 1 . Individual times to reach maximal concentration of paracetamol in plasma, maximal concentration values, and the areas under the plasma paracetamol concentration -time curves (AUC 0 -90 min ) are depicted in Figure 2 .
The time to reach maximal concentration of paracetamol in plasma was significantly longer (300% increase), the maximal observed paracetamol concentrations were significantly lower, and values of AUC 0 -90 min were significantly smaller (95% reduction) during dexmedetomidine infusion than during the morphine and placebo infusion (Table 1) . No statistically significant differences were observed in these parameters between placebo and morphine.
Oro-caecal transit time
Individual oro-caecal transit times are depicted in Figure 2 . Oro-caecal transit times were significantly longer (325% increase) during dexmedetomidine infusion than during morphine and placebo phases (Table 1) . No statistically significant differences were observed between placebo and morphine.
Discussion
Administration of dexmedetomidine markedly inhibited gastric emptying and oro-caecal transit compared with placebo and morphine. The effect of dexmedetomidine on gastrointestinal motility was consistent across all 12 subjects for changes in paracetamol T max , AUC 0 -90 min , and oro-caecal transit time.
Early enteral feeding has been associated with reduced ICU and hospital mortality, 19 but gastrointestinal motility is often inadequate in ICU patients, making nasogastric feeding impossible because of the risk of aspiration. Propofol as single agent and opioid-benzodiazepine combinations are commonly used for ICU sedation. In healthy volunteers, low-dose propofol did not inhibit gastric emptying, 20 21 suggesting that propofol should be relatively safe in this respect, even though oro-caecal transit time was somewhat prolonged. 20 A combination of morphine and midazolam inhibited gastric emptying in critically ill patients compared with propofol. 22 Dexmedetomidine strongly inhibited gastric emptying in healthy volunteers in the present study. This result contrasts with previous results regarding the effects of clonidine in humans. 10 11 However, clonidine is less selective than dexmedetomidine towards a2-adrenoceptors (a1:a2 selectivity ratio 1:200 for clonidine vs 1:1600 for medetomidine) 23 and is also a weaker partial agonist than dexmedetomidine 24 which might contribute to its lesser effect on gastric emptying. Dexmedetomidine has been reported to have either small 7 or no 12 effects on gastric emptying in rodents. This discrepancy could be due to inter-species variation in the effects of dexmedetomidine or differences in dosing.
The dose of dexmedetomidine used in the current study was clinically relevant, at the high end of the recommended dose (0.2 -0.7 mg kg 21 h 21 ) for ICU sedation. When given at lower doses, dexmedetomidine might not inhibit gastric emptying. In the previous study by Memis and colleagues, 9 there was no difference in gastric emptying between ICU patients sedated with dexmedetomidine or with propofol, suggesting that the gastrointestinal effects of the two agents are similar. These findings are in contrast with the present results, as light propofol sedation does not inhibit gastric emptying in healthy volunteers. 20 This study has several limitations. The study involved a rather small number of healthy volunteers, so the results cannot be directly extrapolated to critically ill patients. Another weakness is that we were not able to detect significant differences in the gastrointestinal effects of morphine and placebo. There was a tendency for impaired gastric emptying and gastrointestinal transit after morphine, but the differences compared with placebo were not statistically significant.
Morphine was selected as a control drug because of its wellknown inhibitory effects on gastric emptying 25 and gastrointestinal transit 26 as a positive control. Dexmedetomidine, in turn, was given at the highest dose recommended by the manufacturer for sedation. No statistically significant differences emerged between placebo and morphine in the current study, even though the morphine dose (0.10 mg kg 21 ) was twice that shown to inhibit gastric emptying 25 and gastrointestinal transit 26 in healthy volunteers. We gave morphine as a 20 min infusion in order to avoid high peak plasma concentrations, which could have caused typical opioid adverse effects; this slow infusion might partially explain its unexpectedly small gastrointestinal effects. The morphine treatment arm was included to ensure that the used methods were appropriate to detect drug effects on gastric emptying and gastrointestinal transit. This would have been especially important, had dexmedetomidine not had significant effects. There was a non-significant trend in the expected direction with morphine, but the study was not sufficiently powered to achieve statistical significance for the morphine effect. This does not invalidate the conclusions of the study with regard to dexmedetomidine. For logistic reasons, we wanted to assess the absorption of paracetamol and metabolism of lactulose in the same experimental session-we therefore administered paracetamol and lactulose simultaneously. Lactulose is marketed as a laxative, but it has also been shown to slow gastric emptying. 27 This property of lactulose might have obscured the effect of morphine on gastric emptying compared with placebo, but we have no definitive explanation for why the gastrointestinal effects of morphine did not differ from placebo.
In conclusion, dexmedetomidine markedly inhibited gastric emptying and gastrointestinal transit in healthy volunteers. The clinical significance of this finding should be evaluated in critically ill patients, using clinically relevant doses of dexmedetomidine and relevant comparators, and stratifying for all co-administered drugs.
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